WO2016054053A3 - Hiv-1 antibodies and uses thereof (adcc and bispecific abs) - Google Patents

Hiv-1 antibodies and uses thereof (adcc and bispecific abs) Download PDF

Info

Publication number
WO2016054053A3
WO2016054053A3 PCT/US2015/052963 US2015052963W WO2016054053A3 WO 2016054053 A3 WO2016054053 A3 WO 2016054053A3 US 2015052963 W US2015052963 W US 2015052963W WO 2016054053 A3 WO2016054053 A3 WO 2016054053A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
antibodies
adcc
fragments
bispecific abs
Prior art date
Application number
PCT/US2015/052963
Other languages
French (fr)
Other versions
WO2016054053A2 (en
Inventor
Wilton WILLIAMS
Barton F. Haynes
M. Anthony Moody
Hua-Xin Liao
Guido FERRARI
David EASTERHOFF
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of WO2016054053A2 publication Critical patent/WO2016054053A2/en
Publication of WO2016054053A3 publication Critical patent/WO2016054053A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates, in general, to HIV-1 antibodies including antibodies which bind to the surface of HIV-1 virus infected cells and/or mediate antibody-dependent cellular cytoxicity (ADCC)-, and, in particular, to ADCC-mediating antibodies (and fragments thereof) suitable for use, for example, in reducing the risk of HIV-1 infection in a subject. The invention is directed to bispecific antibody molecules which comprise an arm targeting HIV-1 and a second arm targeting an effector cell. The invention further relates to compositions comprising such antibodies or antibody fragments, and their therapeutic use.
PCT/US2015/052963 2014-09-29 2015-09-29 Hiv-1 antibodies and uses thereof (adcc and bispecific abs) WO2016054053A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056864P 2014-09-29 2014-09-29
US62/056,864 2014-09-29

Publications (2)

Publication Number Publication Date
WO2016054053A2 WO2016054053A2 (en) 2016-04-07
WO2016054053A3 true WO2016054053A3 (en) 2016-05-19

Family

ID=55631354

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2015/052916 WO2016054023A1 (en) 2014-09-29 2015-09-29 Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
PCT/US2015/052963 WO2016054053A2 (en) 2014-09-29 2015-09-29 Hiv-1 antibodies and uses thereof (adcc and bispecific abs)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2015/052916 WO2016054023A1 (en) 2014-09-29 2015-09-29 Hiv-1 antibodies and uses thereof (adcc and bispecific abs)

Country Status (1)

Country Link
WO (2) WO2016054023A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111819196B (en) * 2017-12-21 2022-10-28 纽约市哥伦比亚大学理事会 Bispecific HIV-1 neutralizing antibodies
BR112020016485A2 (en) * 2018-02-15 2020-12-15 Macrogenics, Inc. BINDING MOLECULE, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A DISEASE
CN117597364A (en) * 2021-05-12 2024-02-23 百进生物科技公司 anti-CCR 8 antibodies, antigen-binding fragments thereof, reagents and compositions, and methods of making and using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286112A1 (en) * 2005-05-16 2006-12-21 Sirid-Aimee Kellermann Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
US20070065444A1 (en) * 2005-09-07 2007-03-22 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US20090169562A1 (en) * 2006-06-06 2009-07-02 Mark Throsby Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof
US20110044994A1 (en) * 2009-03-17 2011-02-24 Po-Ying Chan-Hui Human immunodeficiency virus (hiv)-neutralizing antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2926830B1 (en) * 2010-08-31 2017-08-02 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286112A1 (en) * 2005-05-16 2006-12-21 Sirid-Aimee Kellermann Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
US20070065444A1 (en) * 2005-09-07 2007-03-22 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US20090169562A1 (en) * 2006-06-06 2009-07-02 Mark Throsby Human Binding Molecules Having Killing Activity Against Enterococci and Uses Thereof
US20110044994A1 (en) * 2009-03-17 2011-02-24 Po-Ying Chan-Hui Human immunodeficiency virus (hiv)-neutralizing antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GenBank [o] 10 January 2000 (2000-01-10), "Homo sapiens clone 810 immunoglobulin lambda light chain variable region mRNA, partial cds", Database accession no. AF194566 *
DATABASE GenBank [o] 15 October 2014 (2014-10-15), "Homo sapiens clone DH333 immunoglobulin light chain variable region mRNA, partial cds", Database accession no. KM067760 *
DATABASE GenBank [o] 7 June 2007 (2007-06-07), "Homo sapiens clone CBc3bmMK-d4 immunoglobulin mu heavy chain mRNA, partial cds", Database accession no. AY670753 *
DATABASE GenBank [o] 9 August 2015 (2015-08-09), "Homo sapiens clone L002643_H007034_DH195 immunoglobulin light chain variable region mRNA, partial cds", Database accession no. KT304591 *
DATABASE GenBank [o] 9 August 2015 (2015-08-09), "Homo sapiens clone TrH007034_DH195 immunoglobulin heavy chain variable region mRNA, partial cds", Database accession no. KT304359 *

Also Published As

Publication number Publication date
WO2016054023A1 (en) 2016-04-07
WO2016054053A2 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
AU2017206631A8 (en) Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
WO2016033225A3 (en) Antibodies, compositions, and uses
WO2018234793A3 (en) Antibodies
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
EA032929B1 (en) Human immunodeficiency virus neutralizing antibody and methods of use thereof
MX2019006362A (en) Composition comprising two antibodies engineered to have reduced and increased effector function.
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
WO2015138600A3 (en) Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
WO2013188693A8 (en) Antigen binding constructs to cd3
NZ711946A (en) Newcastle disease viruses and uses thereof
WO2013070776A8 (en) Neutralizing gp41 antibodies and their use
AR090973A1 (en) USEFUL ANTIBODIES FOR CANCER DIAGNOSIS
EP4183806A3 (en) Glycan-interacting compounds and methods of use
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
MX341076B (en) Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments.
WO2010056898A3 (en) Rapid expression cloning of human monoclonal antibodies from memory b cells
EP4282881A3 (en) Antibodies against csf-1r
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP3492101A3 (en) Agents for influenza neutralization
WO2016173605A8 (en) Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15847669

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15847669

Country of ref document: EP

Kind code of ref document: A2